Shots: The agreement involves a clinical trial assessing Novartis’s tropifexor and Pfizer’s compounds, including PF-05221304, PF-06865571 & PF-06835919 for treatment of NASH Novartis’ tropifexor (LJN452) is a Farnesoid X receptor (FXR) agonist indicated for NASH and has also received FTD by the US FDA for NASH with liver fibrosis in Oct, 2016 PF-05221304, PF-06865571 & […]Read More
